Skip to main content
Elos Medtech logo

Elos Medtech — Investor Relations & Filings

Ticker · ELOS ISIN · SE0000120776 LEI · 529900I5MSNU451FL670 ST Manufacturing
Open in API
Filings indexed 331 across all filing types
Latest filing 2023-10-19 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ELOS

About Elos Medtech

http://elosmedtech.com

Elos Medtech is a contract development and manufacturing organization (CDMO) specializing in the medical device sector. The company partners with medical technology firms, providing comprehensive services that span the entire product lifecycle, from research and development to manufacturing and commercialization. Its core focus areas include dental, orthopedics, and advanced surgical products. Elos Medtech offers a range of capabilities, including precision manufacturing, polymer injection molding, process optimization, packaging, and regulatory support. The company operates through specialized business units that collaborate to provide clients with tailored solutions, aiming to streamline operations, reduce complexity, and accelerate innovation in the medical device field.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Q3 2023 DELÅRSRAPPORT' (Interim Report), which explicitly identifies it as a quarterly financial report. It contains comprehensive financial statements, including income statements, cash flow data, balance sheet information, and management commentary on business performance for the period of July-September 2023. It is not an announcement of a report (RPA) as it contains the full substantive financial data, nor is it an earnings release (ER) as it provides a detailed, multi-page report structure. Q3 2023
2023-10-19 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Q3 2023 INTERIM REPORT' and contains comprehensive financial statements, key performance indicators, management commentary, and business area analysis for the third quarter of 2023. It is clearly a quarterly financial report, not an announcement or a summary, and contains substantive financial data. Q3 2023
2023-10-19 English
Notice to attend the extraordinary general meeting of Elos Medtech AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Notice to attend the extraordinary general meeting of Elos Medtech AB (publ)". It details the date, time, location, registration procedures, proposed agenda items (including election of Chairman and appointment of a special examiner), and shareholder rights for an Extraordinary General Meeting (EGM). This content directly corresponds to the definition of materials shared during a General Meeting, which aligns best with the 'AGM Information' category (AGM-R), even though it is an EGM, as this code covers general meeting materials. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard proxy statement (DEF 14A/PSI), but a formal notice convening a shareholder meeting.
2023-10-13 English
Kallelse till extra bolagsstämma i Elos Medtech AB (publ)
AGM Information Classification · 99% confidence The document is titled "Kallelse till extra bolagsstämma i Elos Medtech AB (publ)" which translates to "Notice of Extraordinary General Meeting in Elos Medtech AB (publ)". It details the date, time, location, registration procedures, proposed agenda items (including election of chairman and appointment of a special examiner), and voting rights information for an upcoming shareholder meeting. This content directly corresponds to the purpose of a notice for a general meeting, which is to solicit shareholder participation and provide necessary information for voting. This aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI), as it is a formal notice sent to shareholders regarding a meeting where votes will be cast, even though it is not explicitly a DEF 14A (Remuneration) or a DVA (Results). However, given the options, the notice calling for an Extraordinary General Meeting (EGM) and outlining the process and agenda is most closely related to soliciting participation and providing information for voting, making PSI the best fit among the choices, although AGM-R (AGM Information) is also closely related, PSI specifically covers the notice/solicitation aspect.
2023-10-13 Swedish
Myndighetsgodkännanden erhållna för Klingelförvärvet och Företrädesemissionen
Share Issue/Capital Change Classification · 99% confidence The document is a press release written in Swedish announcing that regulatory approvals (Fusionsgodkännande and Tyskt FDI-Godkännande) have been obtained for the acquisition of Klingel and that the conditions for a rights issue (Företrädesemissionen) intended to finance this acquisition have been met. The text explicitly mentions the financing activity (rights issue) and the corporate transaction (acquisition) and discusses the conditions for completion. This strongly aligns with the definition of 'Capital/Financing Update' (CAP), as the core subject is the financing mechanism (rights issue) tied to a major corporate action (acquisition). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). Since it is a formal announcement detailing financing and transaction progress, CAP is the most appropriate classification.
2023-10-02 Swedish
Regulatory approvals obtained for the Klingel Acquisition and the Rights Issue
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that regulatory approvals (Merger Control Clearance and German FDI Clearance) have been obtained for the acquisition of Klingel and that the conditions for the Rights Issue (a financing activity) have been satisfied. It discusses a corporate action (acquisition financed by a rights issue) and regulatory hurdles being cleared. This content strongly relates to capital structure changes, financing activities, and corporate transactions. The most fitting category is 'Capital/Financing Update' (CAP), as the core news is the successful clearance of conditions necessary for the Rights Issue, which is a capital raising event intended to finance the acquisition. It is not a full 10-K, an ER (which focuses on operating results), or a DEF 14A (remuneration). Since it is an announcement about financing and acquisition conditions being met, CAP is the best fit over the general RNS.
2023-10-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.